Replies to post #279580 on Avid Bioservices Inc (CDMO)

[cheynew]

Taylor Schreiber's HTBX had quite a nice run yesterday (up 30% on 10X normal volume) on their announcement:
Heat Biologics to Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results at the International Society for the Study of Lung Cancer Annual Meeting plus they will present a poster reporting topline results, including primary endpoint data, from the Phase II trial evaluating HS-410 (vesigenurtacel-L) in combination with standard of care, Bacillus Calmette-Guérin (BCG), in the treatment of non-muscle invasive bladder cancer (NMIBC) at the Society of Urology Annual Meeting, in San Antonio, TX, on Wednesday, Nov 30th.

When was the last time we jumped 30%?

I looked at Rahul Jasuja's LinkedIn and the only active thing he shows is being a member of the BOD of Pelican Therapeutics. Is that a full time job? He added alot to the PPHM conference calls when he was at Noble.

[biopharm]

... and for an added Friday night bonus: Ramon Valencia recommends Taylor Schreiber for Immunology, Molecular Biology, Cancer..etc...etc...and etc... all just pieces to the much bigger puzzle but have touched on this before.. with Rahul(the PS Targeting pro analyst that jumps on BOD of Pelican...) Taylor Schreiber, Josiah Hornblower...

So what is the probability we have familiar names over at Heat Biologics?

http://www.heatbio.com/about-heat/leadership

No matter what anyone says I find the PAV list at times a big factor....and we have Ms Jin from Intercept as #1 on the PAV list of Ms Kallinteris
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94495465